Published in Clin Lab Haematol on January 01, 1990
Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia. J Clin Pathol (1993) 0.92
Extramedullary hematopoiesis in a sentinel lymph node as an early sign of chronic myelomonocytic leukemia. Case Rep Pathol (2015) 0.75
Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol (1995) 2.63
Allelic imbalance at the LKB1 (STK11) locus in tumours from patients with Peutz-Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence. J Pathol (1999) 2.13
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol (2000) 1.81
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene (2006) 1.74
Effects of genetic screening on perceptions of health: a pilot study. J Med Genet (1992) 1.66
The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease. Gut (2002) 1.50
Purification of the migration stimulating factor produced by fetal and breast cancer patient fibroblasts. Proc Natl Acad Sci U S A (1989) 1.48
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Elastin: mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet (2000) 1.40
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet (2001) 1.29
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet (1998) 1.27
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer (2005) 1.21
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Germline mutations of the LKB1 (STK11) gene in Peutz-Jeghers patients. J Med Genet (1999) 1.16
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Predictive genetic testing in maturity-onset diabetes of the young (MODY). Diabet Med (2001) 1.13
Maternal inheritance pattern of hereditary pancreatitis in patients with pancreatic carcinoma. J Natl Cancer Inst (1999) 1.11
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol (1994) 1.05
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: effect on hyaluronic and synthesis. In Vitro Cell Dev Biol (1989) 1.01
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut (2002) 1.01
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer (2000) 0.99
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology (2001) 0.95
Two sibs with anophthalmia and pulmonary hypoplasia (the Matthew-Wood syndrome). Am J Med Genet (1996) 0.94
A new polymorphism for the RI22H mutation in hereditary pancreatitis. Gut (2001) 0.94
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia (1995) 0.93
Subpopulations of fetal-like gingival fibroblasts: characterisation and potential significance for wound healing and the progression of periodontal disease. Oral Dis (1996) 0.92
Motogenic activity of IGD-containing synthetic peptides. J Cell Sci (1999) 0.91
ONCOPOOL - a European database for 16,944 cases of breast cancer. Eur J Cancer (2010) 0.90
Hereditary pancreatitis and familial pancreatic cancer. Digestion (1997) 0.90
Challenges faced in implementation of a telehealth enabled chronic wound care system. Rural Remote Health (2009) 0.90
The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res (2002) 0.90
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Analysis of short stature homeobox-containing gene ( SHOX) and auxological phenotype in dyschondrosteosis and isolated Madelung deformity. Hum Genet (2001) 0.88
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis (2003) 0.88
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer (1994) 0.88
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant (1993) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Substratum-dependent stimulation of fibroblast migration by the gelatin-binding domain of fibronectin. J Cell Sci (1996) 0.86
Gaucher's disease in the United Kingdom: screening non-Jewish patients for the two common mutations. J Med Genet (1993) 0.86
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
Inter- and intra-site heterogeneity in the expression of fetal-like phenotypic characteristics by gingival fibroblasts: potential significance for wound healing. J Cell Sci (1994) 0.86
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85
Determinants of house dust mite allergen in homes in Wellington, New Zealand. Clin Exp Allergy (1997) 0.85
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia (1999) 0.84
Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer (2010) 0.84
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant (2000) 0.84
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant (2007) 0.84
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant (1997) 0.84
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol (1994) 0.84
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 0.83
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy (2000) 0.83
Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol (1989) 0.82
Information and support needs of women with primary relatives with breast cancer: development of the Information and Support Needs Questionnaire. J Adv Nurs (2001) 0.82
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol (2000) 0.82
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol (1996) 0.82
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia (2012) 0.82
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol (1994) 0.82
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol (2005) 0.81
Effect of erythropoietin in patients with myeloma. BMJ (1990) 0.81
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry (1999) 0.81
Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect (2002) 0.81
Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant (2003) 0.80
DNA repair mechanisms and acute myeloblastic leukemia. Hematol Oncol (2000) 0.80
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol (1992) 0.80
Chemotaxis and Chemokinesis in 3D Macromolecular Matrices : Relevance to Angiogenesis. Methods Mol Med (2001) 0.79
Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation. Clin Lab Haematol (1992) 0.79